Press release: STADA appoints Christos Gallis as Head of Eastern Europe
One document
more
Stories about Medizin, Gesundheit
Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth / Phase II study for BC 007 in the indication Long COVID to start in June
moreCroma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China
Vienna (ots/PRNewswire) - Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active ...
moreFirst Integrated Single-Cell Atlas of the Human Lung
Can a human organ be mapped on a single-cell level to learn about the functionality of each individual cell? And can we learn how different these cells are from person to person? Helmholtz Munich researchers and their collaborators have taken up this challenge and developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and ...
moreLTS Lohmann Therapie-Systeme AG
LTS completes its entry into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business
moreJoint Statement: health organisations define EHDS’ opt-out required for life-saving research
One documentmore
Unraveling the Mode of Action of Tirzepatide
Tirzepatide is a recently approved treatment for type-2 diabetes. Treatment with tirzepatide decreases body weight while improving glucose metabolism in patients with obesity and type-2 diabetes. Although the drug is designed to activate receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), the contribution of activating the GIP receptor in the overall efficacy of ...
more- 2
PM: „Get Airports Ready for Disaster“-Programm in Sarajevo / PR: Get Airports Ready for Disaster Program held in Sarajevo
2 Documentsmore Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe
Vienna (ots/PRNewswire) - Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom ("UK"), and Ireland. Further markets including Brazil will follow by the end of 2023. The anaesthetic cream ...
moreThe Medias Hospital is Raising the Bar for Interventional Oncology as an IASIOS Enrolled Centre
Burghausen/Germany (ots) - The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care. The Medias Hospital has taken the next step to committing to the highest standards when it comes to interventional oncology (IO) care and ...
moreDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
moreBirth weight and head circumference predict IQ and motor performance at 4 years of age
more
Diagnosis of Type 1 Diabetes After SARS-CoV-2 Infection: Researchers Find Possible Correlation
During the COVID-19 pandemic, an increase in the chronic autoimmune disease type 1 diabetes was observed in children, also in Germany. Researchers at Helmholtz Munich and TU Dresden, in cooperation with the Kassenärztliche Vereinigung Bayern (KVB), have now investigated whether there is a temporal association between infection with the SARS-CoV-2 virus and the ...
moreGrünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
moreFruits and vegetables, a priority in the shopping basket
moreDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
moreAmbient ultrafine particles – very small and very dangerous?
A new study conducted by Helmholtz Munich researchers reveals that ultrafine particles, representing the smallest size fraction of particulate air pollution, might be more dangerous to human health than larger particles. These findings add to the growing body of evidence that it may be insufficient to focus on larger particle concentrations and gases when assessing public health risks. It was now published in the ...
more/C O R R E C T I O N -- Croma-Pharma/
Vienna (ots/PRNewswire) - In the news release, Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter, issued 09-May-2023 by Croma-Pharma over PR Newswire, we are advised by the company that the footnote [1] has been updated. The complete, corrected release follows: Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter - ...
more
Amicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
moreFraunhofer-Institut für Produktionstechnologie IPT
Joint expertise from industry and research: New regulations standardize optical coherence tomography
moreBjörn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development
Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...
moreTechnische Universität München
Genetically encoded nano-barcodes
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Electron microscopy: Nano-reporter proteins make invisible processes visible Genetically encoded nano-barcodes - New gene reporter system for electron microscopy - Uses barcodes to identify cellular states and structures that would otherwise remain unidentified - Important step to better elucidate cellular structural changes also in disease How do the nerve cells in our brain communicate with each other? What processes take place ...
moreSuccessful transaction: Adragos Pharma has officially taken over Clinigen’s development unit, Lamda Laboratories near Athens, Greece
Munich / London / Athens (ots) - - Adragos on a growth path: Three locations in Europe and five globally - Acquisition strengthens Adragos' end-to-end integrated pharmaceutical product development service offering - Agreement on further product development activities for Clinigen Munich-based pharmaceutical contract ...
more- 5
Press Release - hubergroup India expands its support for rural healthcare
One documentmore
Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories
Munich / London / Athens (ots) - - Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment - Agreement includes further product development activities for Clinigen Limited - Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally Munich-based pharmaceutical contract ...
moreIEVA (Independent European Vape Alliance)
Health professionals should know the vaping facts
Brussels (ots) - 700,000 people in the EU die each year as a result of smoking and every second smoker dies 14 years prematurely. [1] Switching to vaping has helped millions of smokers worldwide to significantly reduce the harm to their health. The principle of harm reduction works, and millions more smokers could benefit from it. But for it to really change society, smokers need the facts: and that starts with healthcare ...
moreThe world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission
moreSuccessful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan
Munich / Paris / Tokyo (ots) - - Adragos Pharma now third largest pure-play CDMO in the Japanese market - Long-term agreement with Sanofi secures local healthcare supply Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading ...
moreInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
One documentmoreMadeira's public health service SESARAM, EPERAM cooperates with EU project Smart4Health
Potsdam (Germany) (ots) - - Over 260,000 residents and travelers to Madeira Islands can use the digital health solution free of charge - Easy access to healthcare data from the public healthcare services, via a European electronic health record - the Smart4Health platform The Public Health Service of the Autonomous Region of Madeira - SESARAM, EPERAM - has successfully ...
more
Previous567891011121314Next